Peptide-Targeted Radionuclide Therapy (PTRT) using Lu-177 FAP-2286 in Diverse Adenocarcinomas: Feasibility, Biodistribution and Preliminary Dosimetry in a First-in-human study

Conclusions: Our first data demonstrate the feasibility of FAP-targeted theranostics. PTRT using Lu-177 FAP-2286 is - due to long tumor retention - a highly promising treatment option in a broad spectrum of cancers. Further follow-up of patients as well as prospective clinical studies are warranted.

Source: Journal of Nuclear Medicine - May 14, 2020 Category: Nuclear Medicine Authors: Baum, R., Chantadisai, M., Smerling, C., Schuchardt, C., SINGH, A., Eismant, A., Almaguel, F., Mueller, D., Zboralski, D., Osterkamp, F., Hoehne, A., Reineke, U., Kulkarni, H. Tags: New Radiopharmaceuticals Source Type: research